Drug Profile
Buprenorphine - Chiesi Farmaceutici
Alternative Names: Buprenorphine sublingual solution - Chiesi FarmaceuticiLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Chiesi
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Neonatal abstinence syndrome
Most Recent Events
- 06 Aug 2021 Clinical trials in Neonatal abstinence syndrome (In neonates) in Canada (Sublingual) prior to August 2021(Chiesi Farmaceutici pipeline, August 2021)
- 06 Apr 2021 Buprenorphine is still in the phase I/II B-PHORE trial for Neonatal abstinence syndrome (In neonates) in USA (Sublingual) (NCT03608696)
- 11 Jul 2019 Chiesi Farmaceutici S.p.A. completes the phase I/II B-PHORE trial in Neonatal abstinence syndrome (In neonates) in USA (Sublingual) (NCT03608696)